NiCE (NASDAQ:NICE) reported second-quarter 2025 results that surpassed analyst expectations on Thursday, prompting the company to raise its full-year earnings guidance while keeping revenue forecasts ...
TROY, Mich., Nov. 13, 2024 /PRNewswire/ -- NICE's recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities ...
Thousands of patients in England with early-stage chronic heart failure could benefit from earlier access to effective drug therapies under new draft guidance from the National Institute for Health ...
The National Institute for Health and Care Excellence (NICE) has recommended marstacimab (Hympavzi, Pfizer) for treating severe haemophilia B. The treatment is advised for patients aged 12 years and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback